Aberdeen Group’s Palisade Bio PALI Stock Holding History

Aberdeen Group’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.99M	Buy	1,910,205 +1,247,305	+188%	+$2.45M	0.01%	713
2026 Q1	$1.16M	Buy	+662,900	New	+$1.21M	﹤0.01%	809

Other funds holding PALI

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Aberdeen Group's PALI Position: Q2 2026 in Review

Aberdeen Group increased its Palisade Bio (PALI) stake by 188% in Q2 2026, buying an estimated $2.45M and bringing the position to 1,910,205 shares worth $3.99M. The position accounts for 0.01% of the portfolio, ranked #713.

Aberdeen Group first reported a position in PALI in Q1 2026 and has held it in 2 quarters since. 124 funds tracked by Wall St. Rank hold PALI as of Q2 2026.

Aberdeen Group held 1,910,205 shares of Palisade Bio worth $3.99M as of Q2 2026.
Aberdeen Group bought 1,247,305 Palisade Bio shares in Q2 2026, an estimated $2.45M.
Palisade Bio made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #713 holding.
Aberdeen Group first reported a position in Palisade Bio in Q1 2026 and has held it in 2 quarters since.
124 funds tracked by Wall St. Rank held Palisade Bio as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.